UBS maintains Amrize at Neutral, raises price target to $46 from $42
UBS kept Amrize rated Neutral and raised its price target to $46 from $42. The new target suggests 12.5% upside versus the Nov 13 close of $40.89. Recent analyst targets for Amrize range from $35.20 to $52.
How this was made

The 30-second read
Why it matters
A higher target can attract incremental speculative interest, but without new earnings, guidance, or deal information, it is unlikely to drive a sustained repricing.
Market read
Valuation sentiment may improve modestly, but the lack of new fundamentals keeps the trading impact limited.
What to watch
Traders may already have priced in recent target dispersion ($35.20 to $52 over 30 days), reducing incremental impact from UBS’s update.
Background
The piece summarizes UBS’s latest stance on Amrize, including the updated price target and the recent range of other analysts’ targets.
Ticker impact
UBS maintained Amrize at Neutral and raised its price target to $46 from $42, implying a higher valuation versus the Nov 13 close.
Likely mild upward bias as traders price in the higher target, but limited follow-through risk because the rating stays Neutral.
The article provides only an analyst target change and no new company-specific operational or financial disclosure.
Market effects
Minimal, since this is a single-name target change without sector-wide new information.
None indicated.
None indicated.
Counterpoint
Because the rating remains Neutral, the target hike may reflect model recalibration rather than improved fundamentals, limiting upside follow-through.
Key entities
- analyst_firmUBS
Maintained Amrize at Neutral and raised the price target to $46 from $42.
- companyAmrize
Subject of the analyst rating and price-target update.


